Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 7.1% – Time to Buy?

Posted by Geri Gentry on Jun 23rd, 2026

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) was up 7.1% during trading on Tuesday . The company traded as high as $10.59 and last traded at $10.7080. 668,432 shares were traded during mid-day trading, a decline of 54% from the average session volume of 1,449,356 shares. The stock had previously closed at $10.00.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on OLMA shares. Wolfe Research initiated coverage on Olema Pharmaceuticals in a report on Friday, March 27th. They set a “peer perform” rating for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research note on Tuesday, April 21st. TD Cowen reaffirmed a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. HC Wainwright reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research note on Friday, May 22nd. Finally, Guggenheim cut their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Olema Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $44.10.

Check Out Our Latest Stock Analysis on Olema Pharmaceuticals

Olema Pharmaceuticals Stock Performance

The stock has a market cap of $959.54 million, a P/E ratio of -5.43 and a beta of 1.98. The company has a current ratio of 10.88, a quick ratio of 10.88 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $13.25 and a 200 day simple moving average of $19.78.

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.52). On average, equities analysts expect that Olema Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter valued at $1,735,000. Hennion & Walsh Asset Management Inc. grew its position in Olema Pharmaceuticals by 83.2% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 447,046 shares of the company’s stock worth $11,176,000 after acquiring an additional 202,970 shares during the last quarter. Jennison Associates LLC acquired a new position in Olema Pharmaceuticals in the 4th quarter worth about $24,100,000. Kingdon Capital Management L.L.C. acquired a new position in Olema Pharmaceuticals in the 3rd quarter worth about $8,361,000. Finally, Tema Etfs LLC bought a new position in Olema Pharmaceuticals in the fourth quarter valued at about $1,113,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

(Get Free Report)

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.